Assessing the implementation of the recommendations on secondary cardiovascular prevention in patients after myocardial infarction (a pharmaco-epidemiologic study)

Aim. To assess the real clinical practice implementation of the recommendations on secondary cardiovascular disease (CVD) prevention in patients after myocardial infarction (MI).

Material and methods. In total, 6,000 ambulatory medical cards were randomly selected from all cards of the patients visited the city cardiology dispanser in 2006. Among the selected cards, 752 belonged to patients with an MI in anamnesis. The information on main CVD risk factors (RFs), achievement of target levels of body mass index (BMI), blood pressure (BP), total cholesterol (TCH), and low-density lipoprotein CH (LDL-CH), as well as the data on pharmaceutical treatment, invasive diagnostics and therapy of coronary heart disease (CHD), were analysed.

Results. Inadequate attention of ambulatory specialists to the main modifiable and non-modifiable CVD RFs was observed. The prevalence of achieved target levels of BMI, BP, TCH, and LDL-CH was very low. In post-MI patients, anti-aggregants, statins and anticoagulants as a part of the pharmaceutical secondary CVD prevention, were not administered often enough by the specialists working at polyclinics and the cardiology dispanser. The usage of invasive diagnostics and treatment of CHD remained low.

Conclusion. The recommendations on secondary CVD prevention in post-MI patients were implemented inadequately.

1. ВНОК. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза: российские рекомендации. Разработаны Комитетом экспертов Всероссийского научного общества кардиологов. Секция атеросклероза ВНОК 2004; 37 с. www.cardiosite.ru.

2. Оганов Р.Г., Лепахин В.К., Фитилев С.Б. и др., Вторичная профилактика ишемической болезни сердца у пациентов, перенесших инфаркт миокарда, на примере московской популяции. Кардиоваск тер профил 2005; 3(1): 53-60.

3. Оганов Р.Г., Лепахин В.К., Фитилев С.Б. и др., Особенности популяции, диагностика, вторичная профилактика и антиангинальная терапия у пациентов с диагнозом стабильная стенокардия. Кардиоваск тер профил 2006; 1: 49-54.

4. Оганов Р.Г., Лепахин В.К., Фитилев С.Б. и др. Особенности диагностики и терапии стабильной стенокардии в Российской Федерации (международное исследование ATP — Angina Treatment Pattern). Кардиология 2003; 5: 9-15.

5. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 Update. Circulation 2001; 104: 1577-9.

6. AHA Heart Disease and Stroke Statistics: 2004 Update.

7. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular prevention in clinical practice: recommendations of the Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24(17): 1601-10.

8. EUROASPIRE I and II Study Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995-1001.

9. Sans S, Kesteloot H, Kromhout D. The Burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997; 18: 1231-48.